Analysts expect LivaNova PLC (NASDAQ:LIVN) to announce earnings per share (EPS) of $0.71 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for LivaNova’s earnings, with estimates ranging from $0.67 to $0.78. LivaNova posted earnings per share of $0.78 during the same quarter last year, which would indicate a negative year over year growth rate of 9%. The firm is expected to report its next quarterly earnings report on Wednesday, October 30th.
On average, analysts expect that LivaNova will report full year earnings of $2.98 per share for the current fiscal year, with EPS estimates ranging from $2.90 to $3.02. For the next fiscal year, analysts forecast that the firm will report earnings of $3.44 per share, with EPS estimates ranging from $3.30 to $3.53. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover LivaNova.
LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.59 by ($0.03). LivaNova had a negative net margin of 19.64% and a positive return on equity of 9.38%. The company had revenue of $277.20 million for the quarter, compared to the consensus estimate of $275.14 million. During the same period in the prior year, the firm posted $0.96 EPS. The business’s revenue for the quarter was down 3.6% on a year-over-year basis.
In related news, Director Alfred J. Novak sold 1,300 shares of the stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $70.63, for a total transaction of $91,819.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Thad Allen Huston sold 2,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $75.00, for a total value of $150,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 5,300 shares of company stock valued at $387,999. Corporate insiders own 0.41% of the company’s stock.
A number of institutional investors have recently made changes to their positions in LIVN. Creative Financial Designs Inc. ADV bought a new position in LivaNova during the first quarter valued at approximately $29,000. Quadrant Capital Group LLC raised its position in LivaNova by 1,744.8% during the first quarter. Quadrant Capital Group LLC now owns 535 shares of the company’s stock valued at $50,000 after purchasing an additional 506 shares during the period. Financial Gravity Wealth Inc. purchased a new stake in LivaNova during the first quarter valued at approximately $81,000. Quantamental Technologies LLC purchased a new stake in LivaNova during the first quarter valued at approximately $97,000. Finally, Nisa Investment Advisors LLC raised its position in LivaNova by 8.9% during the second quarter. Nisa Investment Advisors LLC now owns 1,900 shares of the company’s stock valued at $137,000 after purchasing an additional 155 shares during the period. 84.08% of the stock is owned by institutional investors.
NASDAQ:LIVN traded down $1.48 during mid-day trading on Friday, hitting $78.63. 11,239 shares of the company traded hands, compared to its average volume of 322,000. The company has a fifty day moving average of $73.04. LivaNova has a one year low of $64.80 and a one year high of $131.54. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.61 and a current ratio of 0.87. The company has a market cap of $3.74 billion, a price-to-earnings ratio of 24.76, a price-to-earnings-growth ratio of 3.25 and a beta of 0.57.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Read More: What Factors Can Affect Return on Equity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.